RSWM
SRPT icon

Robertson Stephens Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Robertson Stephens Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,023
Closed -$240K – 668
2026
Q1 		$240K Sell
11,023
-186
-2% -$3.6K 0.01% 556
2025
Q4 		$241K Buy
+11,209
New +$236K 0.01% 561

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Robertson Stephens Wealth Management's SRPT Position: Q2 2026 in Review

Robertson Stephens Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 11,023 shares — an estimated $240K sold.

Robertson Stephens Wealth Management first reported a position in SRPT in Q4 2025 and held it in 2 quarters. The position peaked at $241K in Q4 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Robertson Stephens Wealth Management reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Robertson Stephens Wealth Management sold 11,023 Sarepta Therapeutics shares in Q2 2026, an estimated $240K.
  • Robertson Stephens Wealth Management first reported a position in Sarepta Therapeutics in Q4 2025 and held it in 2 quarters.
  • Robertson Stephens Wealth Management's Sarepta Therapeutics position peaked at $241K in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Robertson Stephens Wealth Management's 13F filing for Q2 2026, filed 29 Jul 2026.